Literature DB >> 14702533

Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells.

Dave L Roelen1, Danita H Schuurhuis, Daniëlle E M van den Boogaardt, Karin Koekkoek, Paula P M C van Miert, Jolien J van Schip, Sandra Laban, Delphine Rea, Cees J M Melief, Rienk Offringa, Ferry Ossendorp, Frans H J Claas.   

Abstract

BACKGROUND: Activation of immature dendritic cells (DC) in the presence of the glucocorticoid hormone dexamethasone (DEX) results in alternatively matured DC that present antigen in the absence of a proper co-stimulatory context. This maturation process is irreversible, making these cells an attractive potential tool for the induction of antigen-specific T-cell tolerance in vivo. The authors explored the possibility of using these DC for the induction of transplantation tolerance in a fully allogeneic setting in mice.
METHODS: Immature dendritic cells (D1, an immature splenic DC line derived from B6 mice) were pretreated with DEX for 24 hr, after which lipopolysaccharide or nothing was added to the culture for another 48 hr. These cells were analyzed for their in vitro and in vivo stimulating or tolerizing capacities.
RESULTS: In line with their phenotype, including decreased interleukin (IL)-12 production, in vitro co-culture of alternatively matured D1 (B6 origin; H-2b) with completely allogeneic T cells of BALB/c origin led to a significant decrease in the alloreactive T-cell response. A single injection of 1 x 10(6) alternatively matured H-2b DC into BALB/c mice induced a different alloimmune response compared with mature DC. The responding T cells showed a lower proliferation rate and a lower interferon-gamma production, whereas a significantly higher proportion of the cells produced IL-10 as measured ex vivo by enzyme-linked immunospot assay. Furthermore, injection with alternatively matured DC, followed by transplantation of fully mismatched skin grafts (C57BL/6), led to a significantly prolonged survival compared with that of mature DC-pretreated mice or untreated mice. The immunomodulatory effect was antigen specific, as third-party reactive alloresponses were not affected.
CONCLUSIONS: The authors' data constitute the first direct demonstration that DC alternatively matured in the presence of glucocorticoid hormones can be exploited for the specific suppression of the alloreactive Th1 response, resulting in a delayed skin graft rejection in a complete major histocompatibility complex-incompatible strain combination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14702533     DOI: 10.1097/01.TP.0000086340.30817.BA

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

Review 1.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

2.  Dendritic cells treated with crude Plasmodium berghei extracts acquire immune-modulatory properties and suppress the development of autoimmune neuroinflammation.

Authors:  Rodolfo Thomé; Luidy K Issayama; Thiago Alves da Costa; Rosária D Gangi; Isadora T Ferreira; Catarina Rapôso; Stefanie C P Lopes; Maria Alice da Cruz Höfling; Fábio T M Costa; Liana Verinaud
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

Review 3.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

4.  The effects of renal transplantation on circulating dendritic cells.

Authors:  D A Hesselink; L M B Vaessen; W C J Hop; W Schoordijk; J N M Ijzermans; C C Baan; W Weimar
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

5.  Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs.

Authors:  Lesley A Smyth; Kulachelvy Ratnasothy; Aurelie Moreau; Sally Alcock; Pervinder Sagoo; Lucy Meader; Yakup Tanriver; Matthew Buckland; Robert Lechler; Giovanna Lombardi
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

6.  CD8alpha dendritic cells and immune protection from experimental allergic encephalomyelitis.

Authors:  A Pettersson; X-C Wu; C Ciumas; H Lian; V Chirsky; Y-M Huang; B Bjelke; H Link; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Dexamethasone transforms lipopolysaccharide-stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukin-10 production in T cells.

Authors:  Brenda M Bosma; Herold J Metselaar; Nicole M A Nagtzaam; Roel de Haan; Shanta Mancham; Luc J W van der Laan; Ernst J Kuipers; Jaap Kwekkeboom
Journal:  Immunology       Date:  2008-02-27       Impact factor: 7.397

8.  Donor-strain-derived immature dendritic cell pre-treatment induced hyporesponsiveness against allogeneic antigens.

Authors:  Hee Gyung Kang; Jung Eun Lee; Seung Hee Yang; Se Han Lee; Wenda Gao; Terry B Strom; Keunhee Oh; Dong-Sup Lee; Yon Su Kim
Journal:  Immunology       Date:  2009-09-11       Impact factor: 7.397

Review 9.  Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?

Authors:  Brett Phillips; Massimo Trucco; Nick Giannoukakis
Journal:  Clin Dev Immunol       Date:  2011-07-18

10.  Dextromethorphan inhibits activations and functions in dendritic cells.

Authors:  Der-Yuan Chen; Pei-Shan Song; Jau-Shyong Hong; Ching-Liang Chu; I-Horng Pan; Yi-Ming Chen; Ching-Hsiung Lin; Sheng-Hao Lin; Chi-Chen Lin
Journal:  Clin Dev Immunol       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.